Proposed response assessment and endpoints for meningioma clinical trials: Report from the Response Assessment in Neuro-Oncology Working Group Review


Authors: Huang, R. Y.; Bi, W. L.; Weller, M.; Kaley, T.; Blakeley, J.; Dunn, I.; Galanis, E.; Preusser, M.; McDermott, M.; Rogers, L.; Raizer, J.; Schiff, D.; Soffietti, R.; Tonn, J. C.; Vogelbaum, M.; Weber, D.; Reardon, D. A.; Wen, P. Y.
Review Title: Proposed response assessment and endpoints for meningioma clinical trials: Report from the Response Assessment in Neuro-Oncology Working Group
Abstract: No standard criteria exist for assessing response and progression in clinical trials involving patients with meningioma, and there is no consensus on the optimal endpoints for trials currently under way. As a result, there is substantial variation in the design and response criteria of meningioma trials, making comparison between trials difficult. In addition, future trials should be designed with accepted standardized endpoints. The Response Assessment in Neuro-Oncology Meningioma Working Group is an international effort to develop standardized radiologic criteria for treatment response for meningioma clinical trials. In this proposal, we present the recommendations for response criteria and endpoints for clinical trials involving patients with meningiomas.
Journal Title: Neuro-Oncology
Volume: 21
Issue: 1
ISSN: 1522-8517
Publisher: Oxford University Press  
Date Published: 2019-01-01
Start Page: 26
End Page: 36
Language: English
DOI: 10.1093/neuonc/noy137
PUBMED: 30137421
PROVIDER: scopus
PMCID: PMC6303427
DOI/URL:
Notes: Export Date: 1 February 2019 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Thomas Kaley
    154 Kaley